D. Marie Biommune Technolog Com NPV (OTCMKTS:BIMUF) announced the appointment of Thomas R. Gadek to the company’s board. Investors seemed to welcome the news of the Gadek’s appointment going by the reaction on the stock. But impact is Gadek likely to create by sitting on the board of Biommune?
Expectations are high even within the executive
There are high expectations that Gadek’s board position will lead to creation of more value for Biommune shareholders. Patrick Gray, the CEO of Biommune, was quoted in a press release saying the management was pleased that Gadek has won a seat on the board of the company, adding that the expertise that Gadek brings on board will greatly boost the ability of the management to develop life-saving drug products.
“Tom’s demonstrated success as a discovery scientist and his accomplishments in executive leadership make him a perfect fit for our board,” said Gray.
The expectation is that if the contribution leads to more drug discovery and development, Biommune should see its sales grow and its shares rise. That should result in shareholders seeing their value in the company appreciate.
Illustrious career
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
Gadek is a biotechnology veteran, boasting a career spanning 33 years. Some of his work has focused on discovering and developing novel molecules for protein therapeutic targets and he has a long history of success in that field.
Biommune said in a new release that Gadek is an author on some 54 peer-review publications. On top of that, the company said that Gadek is an inventor behind some 64 issued and 76 pending patents in the U.S.
Corporate experience
Besides his work in the laboratories, Biommune said Gadek has had an accomplished career as a corporate leader. He founded SARcode, which developed a successful drug product before it was acquired by Shire.
Prior to founding SARcode, Gadek spent 5 years working for Syntex and another 15 years working for Genentech, which are large and well-known pharmaceutical companies.
Gadek studies chemistry, obtaining a Ph.D. in chemistry from the University of California.
Biommune stock has risen more than 86% YTD.
